GB1583006A - Treatment of animals with a blood volume expander - Google Patents
Treatment of animals with a blood volume expander Download PDFInfo
- Publication number
- GB1583006A GB1583006A GB3870077A GB3870077A GB1583006A GB 1583006 A GB1583006 A GB 1583006A GB 3870077 A GB3870077 A GB 3870077A GB 3870077 A GB3870077 A GB 3870077A GB 1583006 A GB1583006 A GB 1583006A
- Authority
- GB
- United Kingdom
- Prior art keywords
- dextran
- blood volume
- volume expander
- administration
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Description
(54) TREATMENT OF ANIMALS WITH A BLOOD VOLUME EXPANDER
(71) We, FISONS LIMITED, a British Company, of Fison House, 9, Grosvenor Street,
London WIX OAH, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:
This invention relates to a novel method.
A number of animals, and in particular young animals, suffer from scour and in consequence suffer from dehydration and loss of electrolytes. The scour itself has in the past been treated by a number of means, for example the oral administration or im injection of an antibiotic. The loss of electrolytes has also been treated by oral administration of the appropriate salts and water (i.v. infusion not being a very practical procedure with animals), but because of the continuing scour a high proportion of the water and electrolytes are excreted without being absorbed, thus necessitating repeated administration. A continuing problem in aminals suffering from scour has therefore been to enhance the plasma volume quickly to aid the recovery of the animal.
According to the invention there is provided a method of treatment of a domestic animal suffering from dehydration. e.g. caused by scour, which comprises intra-peritoneal administration of a blood volume expander other than dextran or its hydroxyalkyl derivatives.
The animals which may be treated include sheep, cattle, pigs and horses. The method of the invention is particularly applicable to young animals, e.g. animals of less than about 10 weeks old.
The blood volume expander used may be any conventional blood volume expander. e.g. a hydroxyalkyl starch such as hydroxyethyl starch or. a gelatin and is preferably used in aqueous solution. The blood volume expander may be a relatively low molecular weight material. e.g. having a molecular weight of about 40,000 but preferably has a molecular weight of between about 70,000 and 110,000.
According to the invention we also provide a method of treatment of a domestic animal suffering from dehydration, e.g. caused by scour, which comprises sub-cutaneous administration of a blood volume expander.
The blood volume expander for sub-cutaneous administration may be any of those set out above and in addition may be an aqueous solution of a dextran. The dextran may be a relatively low molecular weight dextran. e.g. dextran 40. but is preferably a higher molecular weight dextran. e.g. dextran 70 or dextran 110.
When the blood volume expander is administered sub-cutaneously we prefer it to be administered in admixture with. or after prior administration of, a substance capable of increasing the speed of absorption of fluids. e.g. hyaluronidase.
The blood volume expander may be administered together with oral or im administration of a suitable anti-biotic and/or oral administration of suitable electrolytes.
The volume of the blood volume expander administered to the animal will depend on the particular blood volume expander to be used. the method of administration and the size and condition of the animal. In general a volume of from about 10 to 60 mls and preferably from about t 2 to 25 mls of blood volume expander per kg of animal body weight administered as a single injection is appropriate. The administration may be by conventional sub-cutaneous or intraperitoneal techniques. e.g. in the case of intraperitoneal injection a flutter valve technique may be used. Using such a technique 500 mls of the blood volume expander may be administered over a period of about 5 minutes.
The blood volume expander is preferably administered as soon as possible after the scour has been diagnosed in the animal.
The invention is illustrated, but in no way limited by the following Example.
EXAMPLE
Healthy fourteen week old lambs were used in this experiment. One lamb was used as an untreated control. The remaining lambs were treated as follows:- one with 500 ml of physiological saline, one with 500 ml of dextran 40 injection, one with 500 ml of dextran 70 injection and one with 500 ml of dextran 110 injection. 7 ml samples of blood were taken from the jugular veins of the animals at periods of 2, 18, 24 and 48 hours and 5 and 7 days after injection. The samples were treated with heparin as anticoagulant and were subsequently centrifuged and the remaining plasma analysed for dextran content.
The results of these analysees are shown in the following table in which the dextran content of the plasma is expressed in mg dextran per ml of plasma.
Table
2 hrs 18 hrs 24 hrs 48 hrs 5 days 7 days
Control 0 0.71 0 0 0.17 0 500 ml saline 0.3 0.48 0 0 0.05 0 500 ml dextran 40 0.36 1.31 1.80 2.20 2.07 0.77 500 ml dextran 70 0.53 4.04 5.89 4.40 1.93 0.81 500 ml dextran 110 1.84 4.63 5.42 5.06 3.21 0.63
WHAT WE CLAIM IS:
1. A method of treatment of a domestic animal suffering from dehydration, which comprises intra-peritoneal administration of a blood volume expander other than dextran or its hydroxyalkyl derivatives.
2. A method of treatment of a domestic animal suffering from dehydration, which comprises sub-cutaneous administration of a blood volume expander.
3. A method according to Claim 2. wherein the blood volume expander is administered in admixture with. or after prior administration of. a substance capable of increasing the speed of absorption of fluids.
4. A method according to Claim 3. wherein the substance capable of increasing the speed of absorption of fluids is hyaluronidase.
5. A method according to any one of the preceding claims. wherein the blood volume expander is a hydroxyalkyl starch or a gelatin.
6. A method according to Claim 5. wherein the blood volume expander is a hydroxyethyl starch.
7. A method according to any one of the preceding claims. wherein the blood volume expander has a molecular weight between 70.000 and 110.000.
8. A method according to any one of the preceding claims. wherein the blood volume expander is administered together with oral or im administration of a suitable anti-biotic and/or oral administration of suitable electrolytes.
9. A method according to any one of the preceding claims. wherein from 10 to 60 mls of blood volume expander per kg of animal body weight are administered as a single injection.
10. A method according to Claim 9. wherein from 12 to 25 mls of blood volume expander are administered.
II. A method according to any one of the preceding claims, wherein the dehydration is caused by scour.
12. A method according to any one of the preceding claims, wherein the animal treated is a sheep. cattle. pig or horsc.
13. A method according to any one of Claims 2 to 4. wherein the blood volume expander is dextran.
14. A method according to Claim 13. wherein the dextran is dextran 70 or dextran 110.
15. A method according to Claim 2 and substantially as hereinbefore described in the
Example.
**WARNING** end of DESC field may overlap start of CLMS **.
Claims (15)
- **WARNING** start of CLMS field may overlap end of DESC **.The blood volume expander is preferably administered as soon as possible after the scour has been diagnosed in the animal.The invention is illustrated, but in no way limited by the following Example.EXAMPLE Healthy fourteen week old lambs were used in this experiment. One lamb was used as an untreated control. The remaining lambs were treated as follows:- one with 500 ml of physiological saline, one with 500 ml of dextran 40 injection, one with 500 ml of dextran 70 injection and one with 500 ml of dextran 110 injection. 7 ml samples of blood were taken from the jugular veins of the animals at periods of 2, 18, 24 and 48 hours and 5 and 7 days after injection. The samples were treated with heparin as anticoagulant and were subsequently centrifuged and the remaining plasma analysed for dextran content.The results of these analysees are shown in the following table in which the dextran content of the plasma is expressed in mg dextran per ml of plasma.Table2 hrs 18 hrs 24 hrs 48 hrs 5 days 7 days Control 0 0.71 0 0 0.17 0 500 ml saline 0.3 0.48 0 0 0.05 0 500 ml dextran 40 0.36 1.31 1.80 2.20 2.07 0.77 500 ml dextran 70 0.53 4.04 5.89 4.40 1.93 0.81 500 ml dextran 110 1.84 4.63 5.42 5.06 3.21 0.63 WHAT WE CLAIM IS: 1. A method of treatment of a domestic animal suffering from dehydration, which comprises intra-peritoneal administration of a blood volume expander other than dextran or its hydroxyalkyl derivatives.
- 2. A method of treatment of a domestic animal suffering from dehydration, which comprises sub-cutaneous administration of a blood volume expander.
- 3. A method according to Claim 2. wherein the blood volume expander is administered in admixture with. or after prior administration of. a substance capable of increasing the speed of absorption of fluids.
- 4. A method according to Claim 3. wherein the substance capable of increasing the speed of absorption of fluids is hyaluronidase.
- 5. A method according to any one of the preceding claims. wherein the blood volume expander is a hydroxyalkyl starch or a gelatin.
- 6. A method according to Claim 5. wherein the blood volume expander is a hydroxyethyl starch.
- 7. A method according to any one of the preceding claims. wherein the blood volume expander has a molecular weight between 70.000 and 110.000.
- 8. A method according to any one of the preceding claims. wherein the blood volume expander is administered together with oral or im administration of a suitable anti-biotic and/or oral administration of suitable electrolytes.
- 9. A method according to any one of the preceding claims. wherein from 10 to 60 mls of blood volume expander per kg of animal body weight are administered as a single injection.
- 10. A method according to Claim 9. wherein from 12 to 25 mls of blood volume expander are administered.
- II. A method according to any one of the preceding claims, wherein the dehydration is caused by scour.
- 12. A method according to any one of the preceding claims, wherein the animal treated is a sheep. cattle. pig or horsc.
- 13. A method according to any one of Claims 2 to 4. wherein the blood volume expander is dextran.
- 14. A method according to Claim 13. wherein the dextran is dextran 70 or dextran 110.
- 15. A method according to Claim 2 and substantially as hereinbefore described in the Example.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB3870077A GB1583006A (en) | 1978-05-24 | 1978-05-24 | Treatment of animals with a blood volume expander |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB3870077A GB1583006A (en) | 1978-05-24 | 1978-05-24 | Treatment of animals with a blood volume expander |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1583006A true GB1583006A (en) | 1981-01-21 |
Family
ID=10405162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB3870077A Expired GB1583006A (en) | 1978-05-24 | 1978-05-24 | Treatment of animals with a blood volume expander |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB1583006A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0170275A1 (en) * | 1984-07-31 | 1986-02-05 | Laevosan-Gesellschaft m.b.H. | Peritoneal dialysis solutions |
| WO2001095891A2 (en) * | 2000-06-15 | 2001-12-20 | Stockhausen Gmbh & Co. Kg | Method for treating dehydration and a composition therefor |
| WO2023050297A1 (en) * | 2021-09-30 | 2023-04-06 | 成都夸常奥普医疗科技有限公司 | Topical pharmaceutical composition, application, and kit |
-
1978
- 1978-05-24 GB GB3870077A patent/GB1583006A/en not_active Expired
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0170275A1 (en) * | 1984-07-31 | 1986-02-05 | Laevosan-Gesellschaft m.b.H. | Peritoneal dialysis solutions |
| DE3428201A1 (en) * | 1984-07-31 | 1986-02-06 | Laevosan-Gesellschaft mbH & Co. KG, Linz | PERITONEAL DIALYSIS SOLUTIONS |
| WO2001095891A2 (en) * | 2000-06-15 | 2001-12-20 | Stockhausen Gmbh & Co. Kg | Method for treating dehydration and a composition therefor |
| WO2001095891A3 (en) * | 2000-06-15 | 2002-03-21 | Stockhausen Chem Fab Gmbh | Method for treating dehydration and a composition therefor |
| WO2023050297A1 (en) * | 2021-09-30 | 2023-04-06 | 成都夸常奥普医疗科技有限公司 | Topical pharmaceutical composition, application, and kit |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nordberg et al. | Distribution of Cadmium Among Protein Fractions of Mouse Liver1 | |
| US3984539A (en) | Bovine immunoglobulin isolation process | |
| Sakai | The non‐specific activation of rainbow trout, Salmo gairdneri Richardson, complement by Aeromonas salmonicida extracellular products and the correlation of complement activity with the inactivation of lethal toxicity products | |
| Gavin et al. | Histamine in canine gastric tissues | |
| Lundblad et al. | Chitinase in goat serum: Preliminary purification and characterization | |
| NO930893L (en) | ULTRAS SOUND ADMINISTRATION OF COMPOUNDS IN AQUATIC ANIMALS | |
| JPS5865223A (en) | Composition for endotoxin inactivation | |
| Ross | The diagnosis, prevention and treatment of chronic copper poisoning in housed lambs | |
| GB1583006A (en) | Treatment of animals with a blood volume expander | |
| ATE365043T1 (en) | ENDOTOXIN INHIBITORS FOR THE TREATMENT OF CACHEXIA | |
| Shuster et al. | Lactating cows become partially refractory to frequent intramammary endotoxin infusions: recovery of milk yield despite a persistently high somatic cell count | |
| Hol et al. | Amyloid enhancing factor in hamster. | |
| Gudev et al. | Effect of supplemental Sangrovit on some biochemical indices and leukocytes phagocytic activity in growing pigs | |
| Radostits | Coliform mastitis in cattle | |
| Barri et al. | The toxicity of Crotalaria saltiana to calves | |
| Skarnes | Humoral bactericidal systems: nonspecific and specific mechanisms | |
| Kitazawa et al. | An analysis of mitogenic response of phosphopolysaccharide, a B-cell mitogen produced by Lactococcus lactis ssp. cremoris, to spleen cells | |
| US4837018A (en) | Vaccines for fowl colibacillosis | |
| Florholmen et al. | Effects of endotoxin on the pancreatic ultrastructure | |
| Coleman | Action of Leukocytes and of Brain Tissue on Toxin of B. botulinus: With Note on Peptone Therapy in Experimental Botulism | |
| CA1257203A (en) | Dialysis with monophosphoryl lipid a | |
| RU2768608C1 (en) | Method for the treatment of catarrhal mastitis in cows | |
| D'andrea et al. | Reduced platelet turnover of serotonin in diet restricted migraine patients | |
| DE1902590C2 (en) | Use of an immunoribonucleic acid (IRNS) to immunize live animals | |
| ANDREWS et al. | Some properties of ficin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CSNS | Application of which complete specification have been accepted and published, but patent is not sealed |